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Methotrexate (MTX) is a chemotherapeutic agent that is used to treat a host of malignancies. 
But recently, MTX has also been used as a therapeutic agent for chronic inflammatory disor-
ders such as rheumatoid arthritis, psoriasis, and systemic lupus erythematosus. However, MTX 
is an antimetabolite that affects rapidly dividing normal cells such as oral mucosal epithelial 
cells, gastrointestinal epithelial cells, and bone marrow cells—which explains why oral mucosi-
tis is often an initial manifestation of MTX toxicity. Because oral lesions are frequently initially 
presented in dental clinics, dentists should consider the possibility of adverse drug reactions in 
the differential diagnoses of oral lesions through a meticulous collection of patients’ medical 
histories. In this report, we examine patients who suffered from oral ulcerative lesions upon 
diagnosis of MTX-induced oral mucositis. Then, we suggest approaches for the diagnosis and 
treatment of MTX-induced oral mucositis through a review of literature. 
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INTRODUCTION
Since its introduction over 50 years ago as a treatment 
for childhood acute lymphocytic leukemia, methotrexate 
(MTX) has proved useful as a chemotherapeutic agent for 
various malignancies including hematological and tropho-
blastic malignancies, osteosarcomas, bladder cancer, head 
and neck cancer, lung cancer, and breast cancer.1) MTX is 
also widely used as a therapeutic agent for chronic inflam-
matory disorders such as rheumatoid arthritis (RA),2) psoria-
sis,3) systemic lupus erythematosus,4) granulomatosis with 
polyangiitis (Wegener’s),5) Crohn disease6) and in the pre-
vention of graft-versus-host disease.7)
MTX is a folic acid (FA) antagonist that interferes revers-
ibly with the action of several key enzymes including dihy-
drofolate-reductase, thymidilate synthetase and amino-im-
idazolecarboxamide ribosyl-5-phosphate (AICAR) transfor-
mylase in the folate pathway.8) These enzymes are requisite 
for the synthesis of purines and pyrimidines. MTX’s inhi-
bition of the folate pathway interferences with nucleotide 
synthesis and, consequently, inhibits the cell cycle.
The exact mechanism of MTX in immunological disorders 
has not been fully elucidated. However, it is known that in-
tracellular accumulation of AICAR and homocysteine in-
duces the release of adenosine, which has anti-inflammato-
ry effects and immunosuppressive effects modulated by an 
increase in cyclic adenosine monophosphate.9,10) MTX can 
also modulate the function of immune cells and reduce the 
production of several cytokines (interleukins, tumor-necro-
sis factor, and interferon).2) 
MTX is an antimetabolite that affects rapidly dividing 
normal cells, including oral mucosal epithelial cells, gastro-
intestinal epithelial cells, and bone marrow cells—which ex-
plains why oral mucositis is often an initial manifestation 
of MTX toxicity.11) Myelosuppression is another potential 
side effect of MTX that appears only after long-term ad-
ministration. Myelosuppression is the most feared adverse 
effect of MTX toxicity as it can be fatal.
In this report, we examine patients who suffered from 
oral ulcerative lesions upon diagnosis of MTX-induced oral 
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mucositis. Through our report, we emphasize the impor-
tance of meticulous collection of patients’ medical histories, 
clinical examinations (including laboratory tests), and med-
ical consultations on differential diagnoses of oral ulcer-
ative lesions. Then, we suggest approaches for the diagnosis 
and treatment of MTX-induced oral mucositis through a re-
view of literature. 
CASES REPORT
1. Case 1
A 77-year-old female patient presented with oral ul-
cers that developed two months ago on both buccal mu-
cosa. She has a habit of biting down on her buccal muco-
sa; therefore, she has been afflicted with oral ulcers before. 
She suffers from RA and consequently had undergone to-
tal knee arthroplasty two months ago. Her prescription list 
includes MTX, prednisolone (Solondo Tab.; Yuhanmedica, 
Cheongwon, Korea), leflunomide (Arava Tab.; Sanofi-Aventis 
Korea, Seoul, Korea), celecoxib (Celebrex Cap.; Pfizer, 
Seoul, Korea), rebamipide (Mucosta Tab.; Korea Otsuka 
Pharmaceuticals, Seoul, Korea), and rebeprazole (Pariet Tab.; 
Janssen Korea, Seoul, Korea). She commenced a once-week-
ly dose of 17.5 mg of MTX two years ago. 
Oral examination showed small erosive lesions on both 
buccal mucosa with tenderness to palpation. The clinical 
impression from the patient’s first visit was traumatic ulcers 
due to clenching habits. The patient was prescribed topical 
steroid and sodium-lauryl-sulfate free toothpaste.
Yet in spite of continuous treatment, the patient’s entire 
oral cavity soon exhibited widespread erythema and ulcer-
ation. Oral candidiasis was also suspected on the patient’s 
second visit, which occurred two weeks after her first visit 
(Fig. 1). Upon her second visit, the patient was prescribed 
fluconazole (Diflucan Cap.; Pfizer) and the following labo-
ratory tests were performed: complete blood count (CBC), 
routine chemistry, vitamin B12, folate, serum iron, ferritin, 
zinc.
The laboratory test results revealed that the patient’s red 
blood cell (RBC) count and platelet count had decreased and 
that she was deficient in FA (RBC, 1.83; hemoglobin, 6.6; 
hematocrit [Hct], 20.7; platelet, 128; folate, 2.91). The re-
maining results were within the normal range. 
The patient’s symptoms were getting progressively worse, 
so she was referred to a rheumatologist for MTX toxicity. 
She was advised to not take any more MTX and was pre-
scribed a once-daily dose of 1 mg of FA. The definitive di-
agnosis was oral mucositis due to MTX toxicity.
Fig. 1. Intraoral pictures at the second 
visit (two weeks after first visit). Wide-
spread erythema and ulceration was 
shown on oral cavity.
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Upon review two weeks post-MTX cessation, the patient’s 
symptoms had abated and the ulceration was recovering 
normally (Fig. 2). Laboratory test results were as follows: 
RBC, 3.71; hemoglobin, 12.1; Hct, 36.9. The remaining re-
sults, including platelet count and folate levels, were within 
the normal range. It is clear that pre-existing folate defi-
ciency increases MTX toxicity in the oral mucosa. 
2. Case 2
A 71-year-old-female patient was referred from the de-
partment of rheumatology for evaluation and treatment 
of an oral ulceration that had developed a month ago. The 
patient’s general health was complicated by RA, chronic 
renal failure, hypertension and right hemiplegia due to 
left parietal intracerebral hemorrhage. She was diagnosed 
with RA 15 years ago, and her prescription list included 
MTX, FA (Folcid Tab.; Cho-A Pharm., Seoul, Korea), sul-
fasalazine (Salazopyrin-EN Tab.; Ilsung Pharmaceuticals, 
Seoul, Korea), methylprednisolone (Methylon Tab.; Kunwha 
Pharmaceutical, Seoul, Korea), bisoprolol fumarate (Concor 
Tab.; Merck Korea, Seoul, Korea), hydrochlorothiazide 
(Codiosartan; Yuhan, Seoul, Korea), esomeprazole magne-
sium (Nexium Tab.; AstraZeneca Korea, Seoul, Korea), am-
lodipine besylate+atorvastatin calcium (Caduet Tab.; Pfizer). 
She has taken 10 mg of MTX once weekly for two months—
her medical history revealed that she had previously taken 
Fig. 2. Intraoral pictures at the third visit 
(three weeks after first visit). Wide spread 
erythema and ulceration recovered about 
two weeks after methotrexate cessa tion.
Fig. 3. Intraoral pictures at the first visit. Ulcerative and erythematous lesions were shown on labial and oral mucosa.
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MTX but was forced to discontinue five months ago due to 
pneumonia. Clinical examination revealed ulcerative and 
erythematous lesions involving the labial and oral mucosa 
(Fig. 3). Laboratory test results showed anemia and renal 
dysfunction. The results are as follows: RBC, 2.69; hemoglo-
bin, 9.0; Hct, 27.6; blood urea nitrogen (BUN), 27.4; creati-
nine, 1.49; uric acid, 7.4. The patient was prescribed topical 
steroids and consulted for her anemia and renal dysfunc-
tion. However, her discomfort persisted, so her treatment 
was altered to control for drug side effects. Specifically, one 
week after her first visit, her prescription of MTX was re-
duced to a once-weekly dose of 5 mg. The patient’s ulcer-
ative lesion was resolved two weeks after the decrease in 
MTX (Fig. 4).
3. Case 3
A 68-year-old female patient presented with severe sto-
matitis and the patient was unable to eat for three weeks 
due to her symptoms. The patient could not pinpoint any 
specific reason for her symptoms besides the fact that she 
took stomach ulcer medication three weeks ago. She was di-
agnosed with RA 15 years ago. Her prescription list included 
MTX 15 mg once weekly, FA (Folcid Tab.; Cho-A Pharm.), 
leflunomide (Leflunomide Tab.; Chong Kun Dang Pharm., 
Seoul, Korea), prednisolone (Solondo Tab.; Yuhanmedica), 
rebamipide (Mucosta Tab.; Korea Otsuka Pharmaceuticals), 
Fig. 4. Intraoral pictures at the second visit (three weeks after first visit). The patient’s ulcerative lesions were resolved two weeks after the 
decrease in methotrexate. 
Fig. 5. Intraoral pictures at the first visit. 
Ulcerative and erythematous lesions 
with bleeding tendency were shown on 
entire oral mucosa.
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alprozolam (Xanax Tab.; Pfizer), celecoxib (Celebrex Cap.; 
Pfizer), acetaminophen 325 mg+tramadol HCL 37.5 mg 
(Lapiset; Chong Kun Dang Pharm.), hydrochlorothiazide 
(Dichlozid Tab.; Yuhan) for RA and calcuim carbonate 1,250 
mg+cholecalciferol 1,000 IU (Dicamax Tab.; dalim BioTech, 
Seoul, Korea), atorvastatin calcium (Atorva Tab.; Yuhan), 
fimasartan potassium trihydrate (Kanarb Tab.; Boryung, 
Seoul, Korea), teriparatide (Forsteo Inj.; Eli Lilly, Seoul, 
Korea) for osteoporosis. Clinical examination revealed ul-
cerative and erythematous lesions involving lip, tongue, 
and oral mucosa with bleeding tendencies (Fig. 5). The clin-
ical impression from the patient’s first visit was erythema 
multiforme due to drug side effects. The patient was advised 
to abstain from new drugs for her stomach ulcer and was 
prescribed topical steroids. Three days after her initial visit, 
she received a periodic check for osteoporosis—the laborato-
ry results revealed significant decreases in leukocyte, plate-
let, and erythrocyte counts. In addition, the patient’s renal 
function was found to have decreased. The results were as 
follows: white blood cell, 1.39; RBC, 2.69; hemoglobin, 8.8; 
Hct, 26.8; platelet, 103; BUN, 29.1; creatinine, 1.16. Her fo-
late and hepatic values were within the normal range. The 
patient was referred to the department of hematology for 
further hematologic evaluation due to the discovery of pan-
cytopenia. She was hospitalized and subsequently ceased 
taking MTX. The ulcerative lesion resolved three weeks af-
ter the initial visit and her oral health remained satisfactory 
despite the patient’s resumption of a once-weekly dose of 7.5 
mg of MTX due to her deteriorating RA symptoms.
DISCUSSION
In a previous study, oral mucositis was reported in pa-
tients who were prescribed low-dose MTX but ultimately 
overdosed either due to prescription error or patients’ con-
fusion regarding its once-weekly regime.11,12) In this case 
study, however, MTX toxicity seems to have been elevated 
by several factors such as deficiency of FA,13) reduced re-
nal function,14) and drug interaction,13) even if the dosage 
of MTX does not change. In addition, while oral mucositis 
has commonly been known to appear as an initial sign of 
MTX toxicity, it actually develops relatively late after long-
term MTX administration in our cases. MTX toxicity can 
also prevent healing in previously existing lesions, such as 
traumatic ulcers.15) The oral lesions that had lasted for more 
than a month were resolved within 2 to 3 weeks after dis-
continuation or dose reduction of MTX. Oral lesions that do 
not respond well to treatment require a differential diagno-
sis for toxicity of the drug through the careful collection of 
patient medical history and clinical examinations (including 
laboratory tests).
MTX is generally administered at a weekly dose of 5 to 
25 mg for the management of chronic inflammatory disor-
ders.16) The toxicity of MTX is affected by administration of 
the dosage, the duration of the dosage, the age of the pa-
tient, and his/her renal and hepatic function. Potential risk 
factors for MTX toxicity include pre-existing folate deficien-
cy, hypoalbuminemia, and interaction with other drugs.13) 
For example, aspirin and other nonsteroidal antiinflam-
matory drugs displace MTX from protein and reduce renal 
clearance, increasing blood levels and toxicity.1) Concurrent 
use of proton-pump-inhibitors can also be considered a po-
tential risk factor, but is only reported in cancer patients re-
ceiving high doses of MTX.
Thirty percent to eighty percent of patients on low-dose 
MTX experienced adverse effects due to MTX toxicity,17) 
and 5% to 35% of these patients stopped taking MTX as a 
result.18) However, more severe adverse effects can be recov-
ered relatively easily through administration of folate19) and/
or the dose reduction or cessation of MTX.18) The toxicity 
of MTX can be reversible. It is entirely possible to inter-
rupt MTX for 2 to 3 weeks or take MTX biweekly instead of 
weekly,15) because cessation of MTX may aggravate exist-
ing diseases. Acute toxicity symptoms can be convalesced 
through the administration of an antidote called leucovo-
rin, which is the reduced form of FA.19) Topical treatment 
(i.e., analgesics, antiseptics, or steroids) can also help relieve 
symptoms.15) But, if MTX toxicity persists thereafter, effec-
tive treatment seems difficult. Routine screening labora-
tory tests including CBC, serum folate levels, and a blood 
chemistry profile can be helpful in the prevention of these 
adverse effects in patients treated with low-dose MTX. In 
addition to laboratory tests, we recommend that drugs that 
interact with renal and hepatic function should only be pre-
scribed to patients on low-dose MTX treatment at limited 
doses and under meticulous supervision.
87Hye-Jin Lee, et al. Methotrexate-induced Oral Mucositis
www.journalomp.org
Oral mucositis is a common concern for many patients, 
and dentists are often the first doctors to find out about the 
condition and treat it. Because oral mucositis may be an 
early sign of a more foreboding condition, early recognition 
may help in ensuring effective treatment. It is important to 
perform a thorough evaluation of the patient with oral mu-
cositis and to thus determine the underlying cause of the 
patient’s oral mucositis so that appropriate treatment can 
be implemented in a timely manner. Finding the underly-
ing causes can be done through careful questioning of the 
patient’s medical history and screenings/laboratory tests. 
Dentists should have the ability to determine these under-
lying causes and make a differential diagnosis with similar 
diseases. Dentists also must be aware that oral mucositis 
can be induced by drug toxicity. Furthermore, if systemic 
problems are suspected, referral of the patient to the appro-
priate department of medicine is highly important. 
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